Month: March 2022
Personalized Blood Test to Help Selection of Lung Cancer Treatment
University of Cambridge has led a study that showed that a personalized blood test performed after lung cancer treatment could help in detection of patients [...]
FDA Approves FoundationOne CDx in Non-Small Cell Lung Cancer
U.S. Food and Drug Administration (FDA) has approved the FoundationOne CDx as a companion diagnostic to guide treatment selection for patients with non-small [...]
Dealing with Loss of Appetite in Lung Cancer
One of the most common issues being faced by lung cancer patients is the loss of appetite. It is very common and accounts for 9 out of 10 people with advanced [...]
FDA Approves Nivolumab Plus Chemo as Neoadjuvant Therapy for NSCLC Treatment
The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab is the [...]